Cytek Biosciences Inc provides cell analysis solutions. The company developed high-resolution, high-content and high-sensitivity cell analysis technology called Full Spectrum Profiling. Cytek Biosciences Inc is based in FREMONT, Calif.
| Revenue (Most Recent Fiscal Year) | $200.45M |
| Net Income (Most Recent Fiscal Year) | $-6.02M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 3.42 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 151.58 |
| Pre-Tax Margin (Trailing 12 Months) | -7.87% |
| Net Margin (Trailing 12 Months) | -6.51% |
| Return on Equity (Trailing 12 Months) | -3.35% |
| Return on Assets (Trailing 12 Months) | -2.60% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.17 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.48 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 1.92 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.96 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.05 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.10 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 127.86M |
| Free Float | 114.66M |
| Market Capitalization | $672.57M |
| Average Volume (Last 20 Days) | 1.62M |
| Beta (Past 60 Months) | 1.33 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.33% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.46% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |